Date:3/14/2012

ctations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "could," "potential," "positions," "continue," "expects," "anticipates," "intends," "plans," "believe," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding Trimesta as a treatment option for MS, the statements regarding the estimates of the potential market for oral disease-modifying therapies for MS, the expected results of the clinical study and adequacy of funding. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Synthetic Biologics' forward-looking statements include, among others, our failure to successfully commercialize a new oral therapy for multiple sclerosis, the availability of additional financial and other resources, a failure of our clinical trial to achieve desired results, our failure to obtain FDA approval of oral Trimesta for the treatment of MS and other factors described in Synthetic Biologics' report on Form 10-K for the year ended December 31, 2010 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

'/>"/>

SOURCE Synthetic Biologics, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Synthetic Biologics to Present at ROTH Annual Growth Stock Conference
2. Adeona Becomes Synthetic Biologics, Inc.
3. Startling results in synthetic chemistry presented in Nature Chemistry
4. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
5. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
6. Synthetic Biology: Emerging Global Markets
7. "Sitting Ducks" No Longer: Advance Flu Warning Permits Creation of Replikins Custom Synthetic Flu Vaccine in Animals
8. Synthetic Genomics Inc. and Plenus, S.A. de C.V. Form New Sustainable Agriculture Company, Agradis, Inc. to Develop and Commercialize Products Using Genomic Technologies
9. Swedish University Hospital Improves Monitoring of Treatment Efficacy in Multiple Sclerosis With Synthetic MRI Innovation
10. Kuros Announces Allowance of European Patent for Synthetic Biomaterials
11. Synthetic Genomics Inc. Appoints Joseph Mahler as Chief Financial Officer